Methotrexate treatment for sarcoid-associated panuveitis

Ophthalmology

Volumn 106, Issue 1, 1999, Pages 111-118

  Dev, Sundeep ^a,b   McCallum, Rex M ^a   Jaffe, Glenn J ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b EYE INSTITUTE   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADULT; AGED; ANTERIOR EYE CHAMBER; ARTICLE; CATARACT EXTRACTION; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RETROSPECTIVE STUDY; SAFETY; SARCOIDOSIS; UVEITIS; VISUAL ACUITY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTERIOR CHAMBER; ANTIMETABOLITES, ANTINEOPLASTIC; CATARACT EXTRACTION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PANUVEITIS; RETROSPECTIVE STUDIES; SAFETY; SARCOIDOSIS; VISUAL ACUITY;

EID: 0032608383     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)90011-8     Document Type: Article

References (50)

1. Johns CJ, Scott PP, Schonfeld SA. Sarcoidosis. Annu Rev Med 1989;40:353-71.
2. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986;102:297-301.
3. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978;86:648-55.
4. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996;103:1846-53.
5. Crick RP, Hoyle C, Smellie H. The eyes in sarcoidosis. Br J Ophthalmol 1961;45:461-81.
6. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: Fundamentals and Clinical Practice, 2nd ed. St. Louis: Mosby, 1996;289.
7. Akova YA, Foster CS. Cataract surgery in patients with sarcoidosis-associated uveitis. Ophthalmology 1994;101:473-9.
8. Karma A, Huhti E, Poukkula A. Course and outcome of ocular sarcoidosis. Am J Ophthalmol 1988;106:467-72.
9. Merrill PT, Kim J, Cox TA, et al. Uveitis in the southeastern United States. Curr Eye Res 1997;16:865-74.
10. Wilke WS, Biro JA, Segal AM. Methotrexate in the treatment of arthritis and connective tissue diseases. Cleve Clin J Med 1987;54:327-38.
11. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312: 818-22.
12. Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167-75.
13. Wilke WS, Krall PL, Scheetz RJ, et al. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991;9:581-7.
14. Andersen PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-96.
15. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
16. Krall PL, Mazaneo DJ, Wilke WS. Methotrexate for corticosteroid-resistant polymyalgia rheumatica and giant cell arteritis. Cleve Clin J Med 1989;56:253-7.
17. Healey LA. The current status of methotrexate use in rheumatic diseases. Bull Rheum Dis 1986;36:1-10.
18. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951-60.
19. McMaster PRB, Wong VG, Owens JD, Kyriakos M. Prevention of experimental allergic uveitis. Treatment and methotrexate. Arch Ophthalmol 1975;93:835-7.
20. Holz FG, Krastel H, Breitbart A, et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992;1:142-4.
21. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99:1419-23.
22. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969;67:383-7.
23. Pascalis L, Pia G, Aresu G, et al. Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis. J Autoimmun 1993;6:467-80.
24. Wong VG, Hersh EM. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 1965;69:279-93.
25. Wong VG. Methotrexate treatment of uveal disease. Am J Med Sci 1966;251:149-241.
26. Wong VG, Hersh EM, McMaster PRB. Treatment of a presumed case of sympathetic ophthalmia with methotrexate. Arch Ophthalmol 1966;76:66-76.
27. Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 1980;87:140-50.
28. Belfort R Jr, de Abreu MT, Petrilli AM, et al. Cytotoxic drugs in intermediate uveitis. Dev Ophthalmol 1992;23: 171-6.
29. Soriano FG, Caramelli P, Nitrini R, Rocha AS. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad Med J 1990;66:142-3.
30. Lower EE, Baughman RP, Winget D. The long term use of methotrexate in patients with chronic symptomatic sarcoidosis. Sarcoidosis 1992;9(Suppl 1):465-6.
31. Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med 1968;69:1247-8.
32. Weinreb RN, Tessler H. Laboratory diagnosis of ophthalmic sarcoidosis. Surv Ophthalmol 1984;28:653-64.
33. Baarsma GS, La Hey E, Glasius E, et al. The predictive value of serum angiotensin converting enzyme and lysozyme levels in the diagnosis of ocular sarcoidosis. Am J Ophthalmol 1987;104:211-7.
34. Horsmanheimo M. Correlation of tuberculin-induced lymphocyte transformation with skin test reactivity and with clinical manifestations of sarcoidosis. Cell Immunol 1974; 10:329-37.
35. Hudspith BN, Flint KC, James DG, et al. Lack of immune deficiency in sarcoidosis: compartmentalisation of the immune response. Thorax 1987;42:250-5.
36. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 1959;47 (5 Pt II):155-70.
37. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology Arthritis Rheum 1994;37:316-28.
38. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33:9-18.
39. James DG, Neville E, Langley DA. Ocular sarcoidosis. Trans Ophthalmol Soc UK 1976;96:133-9.
40. James DG. Ocular sarcoidosis. Ann NY Acad Sci 1986;465: 551-63.
41. Rothova A, Suttorp-van Schulter MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6.
42. Palestine AG, Nussenblatt RB, Chan CC. Treatment of intraocular complications of sarcoidosis. Ann NY Acad Sci 1986;465:564-74.
43. Wakefield D, McCluskey P. Cyclosporine: a therapy in ocular inflammatory eye disease. J Ocul Pharmacol 1991;7:221-6.
44. Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976;55:39-65.
45. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991;35:369-85.
46. Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med 1975;82:84-95.
47. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: Fundamentals and Clinical Practice, 2nd ed. St. Louis: Mosby, 1996;111.
48. Sandoval DM, Alarcon GS, Morgan SL. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol 1995; 34(Suppl 2):49-56.
49. Moder KG, Tefferi A, Cohen MD, et al. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995;99:276-81.
50. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34(Suppl 2):20-5.